Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Humana (HUM) to $310 from $300 and keeps an Outperform rating on the shares. The firm notes Humana reported a strong Q1 beat, partially driven by the timing of investments. Nevertheless, the business performed well, with cost-trend remaining in line, while the V28 impact is consistent with initial expectations.